A5060405922- Nanoparticle-Based Drug Delivery
- Metal complexes synthesis and properties
- Drug Transport and Resistance Mechanisms
- Nanoplatforms for cancer theranostics
- Protein Interaction Studies and Fluorescence Analysis
- Click Chemistry and Applications
- RNA Interference and Gene Delivery
- Synthesis and Characterization of Heterocyclic Compounds
- Ferroptosis and cancer prognosis
- Chemical Reactions and Isotopes
- Lanthanide and Transition Metal Complexes
- MicroRNA in disease regulation
- Cancer Mechanisms and Therapy
- Asymmetric Hydrogenation and Catalysis
- Inflammasome and immune disorders
- Metal-Organic Frameworks: Synthesis and Applications
- Advanced Nanomaterials in Catalysis
- Extracellular vesicles in disease
- Radiopharmaceutical Chemistry and Applications
- Phagocytosis and Immune Regulation
- HIV/AIDS drug development and treatment
- Photodynamic Therapy Research Studies
Guangxi Normal University
2022-2025
Zunyi Medical University
2023
To develop a next-generation metal agent and dual-agent multitargeted combination therapy, we developed copper (Cu) compound based on the properties of human serum albumin (HSA)–indomethacin (IND) complex to remodel tumor microenvironment (TME). We optimized series Cu(II) isopropyl 2-pyridyl ketone thiosemicarbazone compounds obtain (C4) with significant cytotoxicity then constructed an HSA–IND–C4 (HSA–IND–C4) delivery system. IND C4 bind hydrophobic cavities IB IIA domains HSA,...
To overcome the resistance of nonsmall cell lung cancer (NSCLC) cells to cisplatin and inhibit their metastasis, we proposed develop a Cu(II) agent based on specific residue(s) HSA nanoparticles (NPs) for multitargeting tumor microenvironment (TME). this end, not only synthesized four 2-hydroxy-3-methoxybenzaldehyde thiosemicarbazone compounds (C1–C4), obtaining Cu compound (C4) with significant cytotoxicity by studying structure–activity relationships, but also revealed binding mechanism C4...
To obtain next-generation metal drugs that can overcome the deficiencies of platinum (Pt) and treat cancer more effectively, we proposed to develop a multitargeted palladium (Pd) agent tumor microenvironment (TME) based on specific residue(s) human serum albumin (HSA). this end, optimized series Pd(II) 2-benzoylpyridine thiosemicarbazone compounds Pd (5b) with significant cytotoxicity. The HSA-5b complex structure revealed 5b bound hydrophobic cavity in HSA IIA subdomain then His-242...
To integrate targeted diagnosis and treatment of cancer, we proposed to develop a gadolinium (Gd) agent based on the properties apoferritin (AFt). this end, not only optimized series Gd(III) 8-hydroxyquinoline-2-carboxaldehyde-thiosemicarbazone compounds obtain compound (C4) with remarkable T1-weighted magnetic resonance imaging (MRI) performance cytotoxicity cancer cells in vitro but also constructed an AFt–C4 nanoparticle (NP) delivery system. Importantly, NPs improved targeting ability C4...
To develop next-generation metal drugs with high efficiency and low toxicity for targeting inhibition of gastric tumor growth metastasis, we not only optimized a series ruthenium (Ru, III) 2-hydroxy-1-naphthaldehyde thiosemicarbazone complexes to obtain Ru(III) complex (4b) remarkable cytotoxicity in vitro but also constructed 4b-decitabine (DCT)/liposome (Lip) delivery system (4b-DCT-Lip). The vivo results showed that 4b-DCT-Lip had stronger capacity inhibit metastasis than 4b-DCT addressed...
To develop next‐generation metal‐based drugs and dual‐drug combination therapy for cancer, we proposed to a copper (Cu) complex that exerts anticancer function by integrating chemotherapy, immunotherapy catalyzes click reaction the in situ synthesis of chemotherapeutic agent, thereby achieving targeted dual‐agent therapy. We designed synthesized tetranuclear Cu(I) (Cu4) with remarkable cytotoxicity notable catalytic ability agent via Cu(I)‐catalyzed azide‐alkyne 1,3‐cycloaddition (CuAAC)....
For the integration of targeted diagnosis and treatment tumor, we innovatively designed synthesized a single-molecule hetero-multinuclear Er(III)–Cu(II) complex (ErCu2) then constructed an ErCu2@apoferritin (AFt) nanoparticle (NP) delivery system. ErCu2 ErCu2@AFt NPs not only provided evident photoacoustic imaging (PAI) signal tumor but also effectively inhibited growth by integrating photothermal therapy, chemotherapy, immunotherapy. improved targeting ability decreased systemic toxicity in...
For more accurate diagnosis and effective treatment of cancer, we proposed to develop a hetero-multinuclear metal complex based on the property apoferritin (AFt) for targeting tumor theranostics by integrating dual-modality imaging multimodality therapy. To this end, rational designed synthesized trinuclear Gd(III)–Cu(II) thiosemicarbazone (Gd-2Cu) then constructed Gd-2Cu@AFt nanoparticle (NP) delivery system. Gd-2Cu/Gd-2Cu@AFt NPs not only had significant T1-weighted magnetic resonance...
To effectively inhibit the growth and metastasis of non-small cell lung cancer (NSCLC) overcome its multidrug resistance (MDR), we designed synthesized a series rhodium (Rh, III) 2-benzoylpyridine thiosemicarbazone complexes. Through studying their structure-activity relationships, identified Rh(III) complex (Rh4) with excellent cytotoxicity against multidrug-resistant cells (A549/ADR cells). Additionally, successfully constructed an apoferritin (AFt) nanoparticle (NP) delivery system...
Abstract Cisplatin resistance is the main cause for failure of cancer therapy. To solve problem, we proposed to develop a novel human serum albumin (HSA) nanoplatform integrate chemotherapy, photothermal therapy (PTT) and immunotherapy. this end, obtained platinum compound (C5) with significant cytotoxicity in cisplatin-resistant SKOV-3 cells (SKOV-3/DDP), then innovatively constructed photosensitizer (indocyanine green (ICG))-encapsulated HSA-C5 complex nanoparticles (ICG@HSA-C5 NPs). The...
To develop next‐generation metal‐based drugs and dual‐drug combination therapy for cancer, we proposed to a copper (Cu) complex that exerts anticancer function by integrating chemotherapy, immunotherapy catalyzes click reaction the in situ synthesis of chemotherapeutic agent, thereby achieving targeted dual‐agent therapy. We designed synthesized tetranuclear Cu(I) (Cu4) with remarkable cytotoxicity notable catalytic ability agent via Cu(I)‐catalyzed azide‐alkyne 1,3‐cycloaddition (CuAAC)....